Laura Joszt, MA

Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.

Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.

A panel of experts provided consumer insights into value-based insurance design (VBID) and how the COVID-19 pandemic may have changed consumer behaviors in a way that VBID may be able to address as the country emerges from the pandemic.

A desire to remove barriers to high-value care and provide services that would improve health and quality of life drove early adopters of value-based insurance design (VBID).

A panel of policy experts, including employees of the previous 2 administrations and a former lobbyist for health plans, discusses achievements of value-based insurance design and how to take the concept to the next level.

Whole-genome sequencing (WGS) is at least as accurate as conventional tests when it comes to genomic profiling in patients with acute myeloid leukemia and myelodysplastic syndromes.

Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.

A review of evidence finds that oxygen therapy may be beneficial for all patients with pulmonary arterial hypertension, not just those who develop severe hypoxemia.

In a briefing, the White House COVID-19 Team discussed the first guidance from the CDC on activities that individuals fully vaccinated against COVID-19 can safely resume, and Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, gave an update on antiretroviral drug development.

Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.

Targeting pulmonary arterial capacitance or compliance can improve overall survival and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to left heart disease (PH-LHD).

Direct inpatient and outpatient costs are significantly higher for patients with untreated spinal muscular atrophy (SMA) compared with matched controls.

Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.

While diagnostic algorithms have evolved in the last decade, there remains an urgent need for innovative therapeutic options to treat systemic sclerosis with pulmonary arterial hypertension.

While only 3 small interfering RNA (siRNA)-based therapies have been approved, the market is poised to expand with 7 other candidates in phase 3 trials.

The FDA has granted priority review of the supplemental New Drug Application for ruxolitinib for the treatment of steroid-refractory chronic graft-versus host disease (GVHD).

Survival among patients with myeloproliferative neoplasm (MPN)–associated pulmonary hypertension (PH) is generally short, although the true prevalence of PH among these patients is poorly understood.

In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.

The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.

Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.

Coverage of the National Association of Accountable Care Organizations (ACOs) fall meeting.

In the real world, the persistence rate with secukinumab to treat psoriatic arthritis was higher than with ustekinumab.

Updated guidance in 6 key areas of asthma care focus on improving diagnosis, management, and treatment.

Combination therapy plays a central role in treating pulmonary arterial hypertension (PAH), and 2 abstracts presented at the CHEST annual meeting highlighted real-world treatment patterns.

Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.

While death rates related to HIV infection declined from 2010 to 2017, differences in HIV-related deaths remain among certain populations.

The shift to treat patients with pediatric-onset multiple sclerosis (POMS) who are treated earlier with a wider variety of medications has led to better outcomes, according to a recent study.

The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.

At its annual meeting, the American College of Rheumatology previewed updates to guidelines for the management of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).

Severe pulmonary arterial hypertension (PAH) was associated with a significantly higher rate of maternal and fetal mortality.